- Cellipont Bioservices said its Texas facility has supported six client cell therapy projects expected to reach Investigational New Drug (IND) application submission in 2026.
- The CDMO provides process and analytical development, GMP manufacturing, quality, testing, and program management support for autologous and allogeneic cell therapy programs.
Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), said its facility in The Woodlands, Texas, has supported six client projects that are expected to reach IND submission in 2026. The company said the milestone reflects progress across multiple cell therapy programs supported by its integrated development and manufacturing services.
For its clients, Cellipont develops fit-for-purpose strategies that can include process optimization, analytical method development, technology transfer, raw material planning, GMP manufacturing, quality control testing, stability support, and preparation of manufacturing and analytical information for regulatory submissions.
The company’s purpose-built Texas facility supports both autologous and allogeneic cell therapy programs from early development through clinical manufacturing. Cellipont said it works with clients as an extension of their teams, with support spanning scientific, technical, operational, and quality functions.
“Our Texas facility has supported a growing portfolio of cell therapy programs, including six client projects currently that are expected to reach IND submission in 2026, which is a meaningful demonstration of the capabilities we have built. Each program has unique scientific and manufacturing requirements, and advancing these IND-enabling efforts in parallel reflects the experience, collaboration, and dedication of our entire team.”
Darren Head, CEO of Cellipont Bioservices
Cellipont said its support is intended to help clients identify risks, maintain program momentum, and prepare cell therapy programs for their next stage of development.
